Micafungin: A sulfated echinocandin

Journal of Antibiotics

Volumn 62, Issue 1, 2009, Pages 27-35

  Hashimoto, Seiji ^a  

^a TOYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

1,3 glucan synthase; Antifungal; Echinocandin; FK463; Micafungin

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ACULEACIN AR; AMPHOTERICIN B; ANTIFUNGAL AGENT; CILOFUNGIN; ECHINOCANDIN; ECHINOCANDIN B; FLUCONAZOLE; FR 131535; FR 133302; FR 179642; FR 190293; FR 209602; FR 209603; FR 209604; FR 220897; FR 220899; FR 227673; FR 901376; FR 901379; FR 901381; FR 901382; MICAFUNGIN; MULUNDOCANDIN; PNEUMOCANDIN BO; SULFATE; UNCLASSIFIED DRUG; WATER;

ACYLATION; ANTIFUNGAL ACTIVITY; ASPERGILLUS; ASPERGILLUS FUMIGATUS; CELL WALL; CLINICAL TRIAL; COLEOPHOMA; COMPETITIVE INHIBITION; DEACYLATION; DRUG SOLUBILITY; ENZYME INHIBITION; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; FUNGUS; HEMOLYSIS; HUMAN; IC 50; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SULFATION; SYNTHESIS; YEAST;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; DRUG DESIGN; ECHINOCANDINS; HUMANS; LIPIDS; LIPOPEPTIDES; MYCOSES; STRUCTURE-ACTIVITY RELATIONSHIP;

COLEOPHOMA EMPETRI; FUNGI;

EID: 62449290386     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2008.3     Document Type: Review

References (46)

1. Clark, T. A. & Hajjeh, R. A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 15, 569-574 (2002).
2. Richardson, M. & Lass-Flörl, C. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. Suppl. 4, 5-24 (2008).
3. Burges, J. L. & Birchall, R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am. J. Med. 53, 77-84 (1972).
4. Carledge, J. D., Midgley, J. & Gazzard, B. G. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidiasis. AIDS 11, 1839-1844 (1997).
5. Aperis, G. & Mylonakis, E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin. Investig. Drugs 15, 579-602 (2006).
6. Nyfeler, R. & Keller-Schierlein, W. Echinocandin Bein neuartiges polipeptide-antibiotikum aus Aspergillus nidulans var.echinatus: Isolierung und Bausteine. Helvet. Chim. Acta. 57, 2459-2477 (1974).
7. Schwartz, R. E., Giacobbe, R. A., Boand, J. A. & Monaghan, R. L. L-671,329, a new antifungal agent. I. Fermentation and isolation. J. Antibiot. 42, 163-167 (1989).
8. Iwamoto,T. et al. WF11899A, B, and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. J. Antibiot. 47, 1084-1091 (1994).
9. Debono, M. et al. The synthesis and evaluation of LY121019: A member of a series of semi-synthetic analogs of the antifungal lipopeptide echinocandin B. Ann. NY Acad. Sci. 544, 152-167 (1988).
10. Debono, M. et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J. Med. Chem. 38, 3271-3281 (1995).
11. Bartizal, K. et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41, 2326-2332 (1997).
12. Denning, D. W. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49, 889-891 (2002).
13. Ikeda, F. et al. Role of micafungin in the antifungal armamentarium. Curr. Med. Chem. 14, 1263-1275 (2007).
14. Hope, W. W., Shoham, S. & Walsh, T. J. The pharmacology and clinical use of caspofungin. Expert Opin. Drug Metab. Toxicol. 3, 263-274 (2007).
15. Chandrasekar, P. H. & Sobel, J. D. Micafungin: a new echinocandin. Clin. Infect. Dis. 42, 1171-1178 (2006).
16. Fujie, A. Discovery of micafungin (FK453): a novel antifungal drug derived from a naural product lead. Pure Appl. Chem. 79, 603-614 (2007).
17. Yamaguchi, H., Hiratani, T., Iwata, K. & Yamamoto, Y. Studies on the mechanism of antifungal action of aculeacin A. J. Antibiot. 35, 210-219 (1982).
18. Debono, M. et al. Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: synthesis of the antifungal agent cilofungin (LY121019). J. Antibiot. 42, 389-397 (1989).
19. Schmatz, D. M. et al. Pneumocandins fromZalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J. Antibiot. 45, 1886-1891 (1992).
20. Iwamoto, T., Fujie, A., Nitta, K., Hashimoto, S., Okuhara, M. & Kohsaka, M. WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties. J. Antibiot. 47, 1092-1097 (1994).
21. Iwamoto, T. Studies on Antifungal Antibiotics Ph.D. Thesis, University of Tokyo (1996).
22. Boeck, L. D., Fukuda, D. S., Abbott, B. J. & Debono, M. Deacylation of echinocandin B by Actinoplanes utahensis. J. Antibiot. 42, 382-388 (1989).
23. Fujie, A. et al. FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties. Bioorg. Med. Chem. Lett. 11, 399-402 (2001).
24. Tomishima, M., Ohki, H., Yamada, A., Maki, K. & Ikeda, F. Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Bioorg. Med. Chem. Lett. 18, 2886-2890 (2008).
25. Tomishima, M., Ohki, H., Yamada, A., Maki, K. & Ikeda, F. Novel echinocandin antifungals. Part 1: Novel side-chain analogs of the natural product FR901379. Bioorg. Med. Chem. Lett. 18, 1474-1477 (2008).
26. Tomishima, M. et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J. Antibiot. 52, 674-676 (1999).
27. Maki, K. et al. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol. Immunol. 52, 383-391 (2008).
28. Denning, D. W. Echinocandin antifungal drugs. Lancet 362, 1142-1151 (2003).
29. Kurtz, M. B. & Douglas, C. M. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35, 79-86 (1997).
30. Hatano, K., Morishita, Y., Nakai, T. & Ikeda, F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. 55, 219-222 (2002).
31. Qadota, H. et al. Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase. Science 272, 279-281 (1996).
32. Nishiyama, Y., Uchida, K. & Yamaguchi, H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J. Electron Microsc. 51, 247-255 (2002).
33. Laverdiere, M., Hoban, D., Restieri, C. & Habel, F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. 50, 119-123 (2002).
34. Ostrosky-Zeichner, L. et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47, 3149-3154 (2003).
35. Tawara, S. et al. In vitro activities of a new lipopeptide antifungal agent FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44, 57-62 (2000).
36. Uchida, K., Nishiyama, Y., Yokota, N. & Yamaguchi, H. In vitro antifungal activity of a novel lipopeptide antifungal agent FK463, against various fungal pathogens. J. Antibiot. 53, 1175-1181 (2000).
37. Nakai, T. et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48, 78-81 (2002).
38. Moudgal, V., Little, T., Boikov, D. & Vazquez, J. A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49, 767-769 (2005).
39. Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R. & Walsh, T. J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. 45, 3310-3321 (2001).
40. Pettengell, K., Mynhardt, J., Kluyts, T., Lau, W., Facklam, D. & Buell, D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther. 20, 475-481 (2004).
41. de Wet, N. et al. A randomized, doubleblind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIVpositive patients. Clin. Infect. Dis. 39, 842-849 (2004).
42. de Wet, N. T. et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. 21, 899-907 (2005).
43. Kanasaki, R. et al. FR209602 and related compounds, novel antifungal lipopeptides from Coleophoma crateriformis no.738. I. Taxonomy, fermentation, isolation and physico-chemical properties. J. Antibiot. 59, 137-144 (2006).
44. Kanasaki, R. et al. FR220897 and FR220899, novel antifungal lipopeptides from Coleophoma empetri no. 14573. J. Antibiot. 59, 149-157 (2006).
45. Kanasaki, R. et al. FR227673 and FR190293, novel antifungal lipopeptides from Chalara sp. No. 22210 and Tolypocladium parasiticum No. 16616. J. Antibiot. 59, 158-167 (2006).
46. Hino, M. et al. Chemical diversity in lipopeptide antifungal antibiotics. J. Ind. Microbiol. Biotechnol. 27, 157-162 (2001).